Targeted Prostate Cancer Healthcheck

Project Summary

The Targeted Prostate Health Check (TPHC) project supports NHS England’s post-pandemic cancer recovery objectives and also the Long Term Plan cancer ambition to diagnose 75% of all cancers at an earlier stage, by 2028.

During the Covid-19 pandemic, there has been a shortfall in prostate cancer referrals with a slower recovery to pre-pandemic levels. Local data analysis shows there is a shortfall of approximately 205 prostate cancer first treatments in North East London.

The primary aim is to case find prostate cancers that have not been identified during Covid-19. A stratified list of high risk patients will be invited to a prostate health check clinic based at Mile End Hospital for a consultation and clinical assessment. It will be necessary to process patient identifiable information to identify high risk patients who will need to be contacted and offered this service.

The expected outcome is to find the prostate cancer patients across NEL who have not been identified since Covid-19, and subsequently reduce the prostate cancer treatment gap.

Project population

Male patients within North East London.

Project cohort

Include:

• Black African and Caribbean men aged > 45-74 years. Ethnicity codes for this cohort: M, N, P, PA,PB, PC, PD, PE
• Black African and Caribbean men aged > 45-74 years with family history of prostate cancer. Ethnicity codes for this cohort: M, N, P, PA,PB, PC, PD, PE
• Men of any other ethnicity (excluding black African and Caribbean) aged >45-74
• Men of any other ethnicity (excluding black African and Caribbean) aged >45-74 with family history of prostate cancer
• Men aged 39> with BRCA1 gene mutation.
• Men aged 39> with BRCA2 gene mutation.

Exclude:

• Deceased patients.
• Previous or current prostate cancer diagnosis (any kind of prostate cancer).

Project criteria

• Generic Primary Care data
  • NHS Number
  • Name
  • Address
  • Patient Demographics (including contact details)
  • DOB
  • Gender
  • GP Practice & address/phone number
  • CCG/Borough
• Medical History
  • Family history of prostate cancer
  • Family history of breast cancer
  • BRCA1 gene mutation
  • BRCA2 gene mutation
  • Benign Prostatic hyperplasia
• Investigations
  • Prostate Specific Antigen (PSA) test
  • Body Mass Index
  • Urea
  • Creatinine
  • GFR
  • INR

Exclusions:

• Diagnosis of prostate cancer
• Prostatectomy
• Radical prostate radiotherapy
• Prostate brachytherapy

Data state

Patient identifiable.

Back to Case studies